Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.

Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL.

Open source

DOI: 10.1002/cam4.4260
Published: 2021-09-21
Container: Cancer Med
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.4260,
  title = {Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.},
  author = {Oaknin A and  Oza AM and  Lorusso D and  Aghajanian C and  Dean A and  Colombo N and  Weberpals JI and  Clamp AR and  Scambia G and  Leary A and  Holloway RW and  Amenedo Gancedo M and  Fong PC and  Goh JC and  O'Malley DM and  Armstrong DK and  Banerjee S and  García-Donas J and  Swisher EM and  Cameron T and  Maloney L and  Goble S and  Ledermann JA and  Coleman RL.},
  year = {2021},
  journal = {Cancer Med},
  doi = {10.1002/cam4.4260},
  url = {https://doi.org/10.1002/cam4.4260}
}

RIS

TY  - JOUR
TI  - Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
AU  - Oaknin A
AU  -  Oza AM
AU  -  Lorusso D
AU  -  Aghajanian C
AU  -  Dean A
AU  -  Colombo N
AU  -  Weberpals JI
AU  -  Clamp AR
AU  -  Scambia G
AU  -  Leary A
AU  -  Holloway RW
AU  -  Amenedo Gancedo M
AU  -  Fong PC
AU  -  Goh JC
AU  -  O'Malley DM
AU  -  Armstrong DK
AU  -  Banerjee S
AU  -  García-Donas J
AU  -  Swisher EM
AU  -  Cameron T
AU  -  Maloney L
AU  -  Goble S
AU  -  Ledermann JA
AU  -  Coleman RL.
PY  - 2021
JO  - Cancer Med
DO  - 10.1002/cam4.4260
UR  - https://doi.org/10.1002/cam4.4260
ER  -

APA

A, O., AM, O., D, L., C, A., A, D., N, C., JI, W., AR, C., G, S., A, L., RW, H., M, A. G., PC, F., JC, G., DM, O., DK, A., S, B., J, G., EM, S., T, C., L, M., S, G., JA, L., & RL., C. (2021). Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.. Cancer Med. https://doi.org/10.1002/cam4.4260

Source records

europe-pmc · retrieved 2026-09-25T20:21:54.795Z